ABOS
Acumen Pharmaceuticals, Inc.
Next earnings Aug 10, 2026 · consensus $-0.37 EPS
Last earnings +8.8% on 2026-05-12
$2.36
▲ +6.79%$2.36▲ +110.71%
over 1Y
L $1.11EODHDH $3.37
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+6.8%
1W+6.8%
1M-7.1%
3M+4.4%
YTD+16.8%
1Y+110.7%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 12 analysts
Strong Buy
Conservative balance sheet (liabilities/equity 0.74x).
Return on equity -172.3% · latest
Acumen Pharmaceuticals, Inc. shows limited reported revenue, and -172.3% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$19.6M | -$45.2M | -$61.1M | -$114M | -$124M |
| Net income | -$101M | -$42.9M | -$52.4M | -$102M | -$121M |
| Diluted EPS | -$5.02 | -$1.06 | -$1.08 | -$1.71 | -$2.00 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$148M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-71.2%
FCF yield-67.8%
Quality & risk
ROIC (est.)-96.3%
Free cash flow-$116M
Total debt$31.2M
Net cash$22.8M
Piotroski F-Score1/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+19.2%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-152026-06-17open ↗144Filing2026-06-17open ↗144Filing2026-06-16open ↗8-KPeriod ending 2026-06-122026-06-16open ↗144Filing2026-06-15open ↗4Period ending 2026-06-092026-06-10open ↗144Filing2026-06-09open ↗4Period ending 2026-06-032026-06-05open ↗4Period ending 2026-06-032026-06-05open ↗4Period ending 2026-06-032026-06-05open ↗4Period ending 2026-06-032026-06-05open ↗4Period ending 2026-06-032026-06-05open ↗
Frequently asked
- Is Acumen Pharmaceuticals, Inc. (ABOS) a buy?
- ABOS currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.74x).
- What is Acumen Pharmaceuticals, Inc.'s quality score?
- ABOS scores 34.641025641025635/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001576885, latest 10-Q filed 2026-05-12) · EODHD · as of 6/26/2026, 6:53:08 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.